Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial.
Ther Adv Respir Dis
; 14: 1753466620968500, 2020.
Article
in En
| MEDLINE
| ID: mdl-33167780
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quinuclidines
/
Benzyl Alcohols
/
Bronchodilator Agents
/
Chlorobenzenes
/
Muscarinic Antagonists
/
Pulmonary Disease, Chronic Obstructive
/
Adrenergic beta-2 Receptor Agonists
/
Salmeterol Xinafoate
/
Lung
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ther Adv Respir Dis
Journal subject:
PNEUMOLOGIA
/
TERAPEUTICA
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: